^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Cancer
    Regimen:GEM-CAP (capecitabine + gemcitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Metastatic Pancreatic Cancer: ASCO Guideline Update

    Published date:
    08/05/2020
    Excerpt:
    Recommendations…First-Line Treatment…Gemcitabine plus nab-paclitaxel is recommended…Recommendations…First-Line Treatment…Gemcitabine alone is recommended…The addition of nabpaclitaxel or capecitabine or erlotinib to gemcitabine may be offered in this setting…
    DOI:
    10.1200/JCO.20.01364 Journal of Clinical Oncology